Dr. Stephen W. Halpern, MD
Cardiology (Cardiovascular Disease Physician)
4740 Hoen Ave
Santa Rosa, CA 95405
Who else practices at this address →
Sonoma County includes mental health (39% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Georgetown University School of Medicine (1972)
- Years since graduation
- 54
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 562
Licensed in California since 1975, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1972Medical school: Georgetown University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
CA license G30604 (first issued 1975; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence Santa Rosa Memorial Hospital Santa Rosa, CA
- Healdsburg Hospital Healdsburg, CA
Medical groups
- Providence Medical Foundation (1,466 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 562
- Services billed
- 2,246
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 813 | 326 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 296 | 230 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 230 | 228 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 124 | 95 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 111 | 110 |
| New patient office or other outpatient visit, 45-59 minutes | 97 | 97 |
| Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | 71 | 69 |
| Heart rhythm recording of continous external ekg over 8-15 days | 53 | 52 |
| Programming of dual lead pacemaker system | 32 | 21 |
| Established patient office or other outpatient visit, 20-29 minutes | 30 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Santa Rosa, CA | 439 |
| Eliquis (apixaban) Other prescribers in Santa Rosa, CA | 241 |
| Rosuvastatin Calcium Other prescribers in Santa Rosa, CA | 228 |
| Amlodipine Besylate Other prescribers in Santa Rosa, CA | 159 |
| Hydrochlorothiazide Other prescribers in Santa Rosa, CA | 112 |
| Lisinopril Other prescribers in Santa Rosa, CA | 88 |
| Ezetimibe Other prescribers in Santa Rosa, CA | 87 |
| Entresto (sacubitril/valsartan) Other prescribers in Santa Rosa, CA | 78 |
| Repatha Sureclick (evolocumab) Other prescribers in Santa Rosa, CA | 74 |
| Metoprolol Succinate Other prescribers in Santa Rosa, CA | 73 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 64 payments worth $1,625 in total to this clinician.
| Merck Sharp & Dohme LLC | $223 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $211 |
| Boston Scientific Corporation | $186 |
| Edwards Lifesciences Corporation | $165 |
| Pfizer Inc. | $162 |
| Bayer HealthCare Pharmaceuticals Inc. | $106 |
| Esperion Therapeutics, Inc. | $88.82 |
| Abbott Laboratories | $76.10 |
| Food and Beverage | $1,585 |
|---|---|
| Education | $40.44 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Jan 9, 2025 | Education Kerendia · Cardio-Renal · in-kind | $20.22 |
| Bayer HealthCare Pharmaceuticals Inc. Feb 25, 2025 | Education Kerendia · Cardio-Renal · in-kind | $20.22 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $361,797 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc. - A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)
Janssen Research & Development, LLC - Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
E.r. Squibb & Sons, L.l.c. · Completed · NCT04036435 - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.